Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $110.65 million. The enterprise value is $116.29 million.
| Market Cap | 110.65M |
| Enterprise Value | 116.29M |
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 24.16 million shares outstanding. The number of shares has increased by 24.66% in one year.
| Current Share Class | 24.16M |
| Shares Outstanding | 24.16M |
| Shares Change (YoY) | +24.66% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 18.54% |
| Owned by Institutions (%) | 43.56% |
| Float | 13.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.62 |
| Forward PS | 1.52 |
| PB Ratio | 7.64 |
| P/TBV Ratio | 7.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 1.88.
| Current Ratio | 3.47 |
| Quick Ratio | 2.97 |
| Debt / Equity | 1.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.80 |
Financial Efficiency
Return on equity (ROE) is -193.58% and return on invested capital (ROIC) is -24.67%.
| Return on Equity (ROE) | -193.58% |
| Return on Assets (ROA) | -19.13% |
| Return on Invested Capital (ROIC) | -24.67% |
| Return on Capital Employed (ROCE) | -35.84% |
| Weighted Average Cost of Capital (WACC) | 15.21% |
| Revenue Per Employee | $310,832 |
| Profits Per Employee | -$91,664 |
| Employee Count | 220 |
| Asset Turnover | 1.48 |
| Inventory Turnover | 6.44 |
Taxes
In the past 12 months, Exagen has paid $87,000 in taxes.
| Income Tax | 87,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.35% in the last 52 weeks. The beta is 2.02, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 2.02 |
| 52-Week Price Change | -32.35% |
| 50-Day Moving Average | 3.87 |
| 200-Day Moving Average | 5.96 |
| Relative Strength Index (RSI) | 55.13 |
| Average Volume (20 Days) | 308,349 |
Short Selling Information
The latest short interest is 864,742, so 3.58% of the outstanding shares have been sold short.
| Short Interest | 864,742 |
| Short Previous Month | 716,154 |
| Short % of Shares Out | 3.58% |
| Short % of Float | 6.26% |
| Short Ratio (days to cover) | 1.31 |
Income Statement
In the last 12 months, Exagen had revenue of $68.38 million and -$20.17 million in losses. Loss per share was -$0.88.
| Revenue | 68.38M |
| Gross Profit | 39.88M |
| Operating Income | -14.12M |
| Pretax Income | -20.08M |
| Net Income | -20.17M |
| EBITDA | -11.84M |
| EBIT | -14.12M |
| Loss Per Share | -$0.88 |
Balance Sheet
The company has $21.51 million in cash and $27.15 million in debt, with a net cash position of -$5.63 million or -$0.23 per share.
| Cash & Cash Equivalents | 21.51M |
| Total Debt | 27.15M |
| Net Cash | -5.63M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | 14.43M |
| Book Value Per Share | 0.60 |
| Working Capital | 31.02M |
Cash Flow
In the last 12 months, operating cash flow was -$13.37 million and capital expenditures -$756,000, giving a free cash flow of -$14.13 million.
| Operating Cash Flow | -13.37M |
| Capital Expenditures | -756,000 |
| Depreciation & Amortization | 2.28M |
| Net Borrowing | 2.72M |
| Free Cash Flow | -14.13M |
| FCF Per Share | -$0.58 |
Margins
Gross margin is 58.32%, with operating and profit margins of -20.65% and -29.49%.
| Gross Margin | 58.32% |
| Operating Margin | -20.65% |
| Pretax Margin | -29.36% |
| Profit Margin | -29.49% |
| EBITDA Margin | -17.32% |
| EBIT Margin | -20.65% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.66% |
| Shareholder Yield | -24.66% |
| Earnings Yield | -18.22% |
| FCF Yield | -12.77% |
Analyst Forecast
The average price target for Exagen is $8.57, which is 87.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.57 |
| Price Target Difference | 87.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 10.61% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -4.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.98 |
| Piotroski F-Score | 3 |